397 related articles for article (PubMed ID: 27766784)
1. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y
Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784
[TBL] [Abstract][Full Text] [Related]
2. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
Feng S; Wang Y; Cai K; Wu H; Xiong G; Wang H; Zhang Z
PLoS One; 2015; 10(10):e0140794. PubMed ID: 26474174
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Analysis of Icotinib on Beneficiary of
Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].
Jiang X; Wang W; Zhang Y
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):200-6. PubMed ID: 27118647
[TBL] [Abstract][Full Text] [Related]
4. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
6. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
7. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
11. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the Efficacy and Safety of Icotinib with Standard Second-line
Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer].
Yao S; Qian K; Wang R; Li Y; Zhang Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):369-73. PubMed ID: 26104894
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
Shao L; Zhang B; He C; Lin B; Song Z; Lou G; Yu X; Zhang Y
Chin Med J (Engl); 2014; 127(2):266-71. PubMed ID: 24438614
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
Biaoxue R; Hua L; Wenlong G; Shuanying Y
Oncotarget; 2016 Dec; 7(52):86902-86913. PubMed ID: 27893423
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
[TBL] [Abstract][Full Text] [Related]
19. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
20. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Zhou L; He J; Xiong W; Liu Y; Xiang J; Yu Q; Liang M; Zhou X; Ding Z; Huang M; Ren L; Zhu J; Li L; Hou M; Ding L; Tan F; Lu Y
Lung Cancer; 2016 Jun; 96():93-100. PubMed ID: 27133757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]